Electron Beam Therapy: Procedure, Uses, Side Effects & Cost — Cost, Top Hospitals & Success Rates | MyMedicPlus

Electron beam therapy (also called electron therapy or electron beam radiotherapy) is a specialised form of external beam radiation that uses streams of high-energy electrons generated by a medical linear accelerator (LINAC) to destroy cancer cells. Unlike photon (X-ray) beams that penetrate deeply through the body, electrons deposit the majority of their energy within a predictable, shallow depth determined by beam energy — and then stop abruptly. This characteristic finite range makes electron therapy uniquely suited for treating superficial tumours while sparing the underlying healthy tissues from significant radiation dose.

In clinical practice, electrons are selected when the target lesion lies within approximately 1–6 centimetres of the skin surface. The relationship between electron energy (measured in megaelectronvolts, or MeV) and treatment depth follows a consistent rule: the depth of maximum dose in centimetres is roughly one-third of the beam energy in MeV. Thus a 6 MeV beam treats a lesion at approximately 2 cm depth, while a 15 MeV beam reaches approximately 5 cm.

Modern linear accelerators are designed to switch seamlessly between photon and electron modes during the same treatment session, giving radiation oncologists exceptional flexibility to design individualised treatment plans. Electron beams are shaped using custom-fabricated cerrobend blocks or electron applicators — rectangular collimating devices that attach directly to the LINAC gantry to conform the treatment field precisely to the target volume while protecting adjacent normal structures.

Electron therapy has been a cornerstone of radiation oncology for over five decades, with a well-established safety and efficacy profile validated in thousands of clinical trials and millions of patient treatments worldwide.

Electron beam radiation is appropriate for a defined set of clinical scenarios where the tumour location — superficial, accessible, and not requiring deep tissue penetration — matches the physical properties of electron beams.

• Skin Cancers: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin, particularly on the face, scalp, ears, or nose where surgery would cause cosmetically significant deformity. Electron therapy achieves local control rates of 90–95% for T1-T2 skin lesions with excellent cosmetic outcomes.
• Breast Cancer — Tumour Bed Boost: After whole-breast irradiation with photons following lumpectomy (breast-conserving surgery), a boost dose of 10–16 Gy delivered by electrons to the surgical cavity (tumour bed) reduces local recurrence rates by 40–50% compared to whole-breast radiation alone. The boost targets the highest-risk zone for recurrence while electron beam fall-off protects the lung and heart.
• Chest Wall Irradiation: Post-mastectomy radiation of the chest wall uses electrons to treat the 4–6 mm skin and subcutaneous tissue at risk for locoregional recurrence while protecting the underlying lung from high photon doses.
• Merkel Cell Carcinoma: A rare but aggressive neuroendocrine skin cancer highly sensitive to radiation. Electron therapy is used for adjuvant treatment of the primary tumour site and regional nodes.
• Lip Cancers and Oral Cavity Lesions: Superficial squamous cell carcinomas of the lip benefit from electron therapy; an intra-oral electron cone applicator precisely directs dose to the lesion while teeth and mandible are shielded.
• Total Skin Electron Therapy (TSET): A specialised technique delivering low-energy electrons (4–6 MeV) to the entire skin surface for mycosis fungoides (cutaneous T-cell lymphoma), achieving complete response in 80–95% of early-stage disease.
• Keloid Scars: Post-surgical electron radiation (12–20 Gy) immediately after keloid excision reduces recurrence rates from 70–80% (surgery alone) to below 15%.

Radiation oncologists carefully evaluate each patient's tumour characteristics, overall health, and treatment goals to determine whether electron therapy is appropriate.

Ideal candidates for electron therapy include:

• Patients with superficial cancers (skin, lip) who are poor surgical candidates due to age, anticoagulation, comorbidities, or unfavourable anatomical location
• Breast cancer patients after lumpectomy requiring a localised boost to the tumour bed
• Post-mastectomy patients requiring chest wall irradiation
• Patients with cutaneous T-cell lymphoma (CTCL/mycosis fungoides) requiring total skin irradiation
• Patients with keloids following surgical excision who need adjuvant radiation to prevent recurrence

Relative contraindications include:

• Previous radiation to the same site (cumulative dose limits must be respected to avoid tissue necrosis)
• Active connective tissue disorders such as scleroderma or systemic lupus erythematosus (radiation sensitivity increased)
• Pregnancy — radiation therapy is generally deferred until after delivery unless delay would endanger the mother's life
• Deep tumours beyond 6 cm — photon-based treatments (IMRT, VMAT, proton therapy) are more appropriate
• Poorly controlled diabetes in the treatment field — impaired wound healing may worsen acute skin reactions

All patients undergo simulation CT scanning in treatment position before commencing electron therapy, allowing the radiation oncology team to measure target depth accurately and select the optimal electron energy for the specific anatomical site.

Electron therapy is delivered as a course of outpatient treatments (fractions) administered on a daily or twice-daily basis depending on the clinical indication and department protocol.

Standard fractionation schemes by indication:

• Skin BCC/SCC: 45–50 Gy in 15–20 daily fractions of 2.25–2.5 Gy; or hypofractionated regimens such as 35 Gy in 5 weekly fractions for elderly patients. Treatment fields include a 1–2 cm clinical target volume margin around the visible tumour.
• Breast tumour bed boost: 10–16 Gy in 4–8 fractions of 2 Gy, delivered after completion of whole-breast photon radiation. The electron energy (usually 9–12 MeV) is selected to match the measured depth of the tumour bed surgical cavity.
• Post-mastectomy chest wall: 40–50 Gy in 15–25 fractions using 6–9 MeV electrons, often with bolus material (tissue-equivalent wax layer) placed on the skin to ensure adequate surface dose.
• Total Skin Electron Therapy (TSET): 36 Gy in 36 fractions delivered over 8–10 weeks using a modified Stanford technique; the patient stands in multiple positions at an extended source-to-skin distance to achieve uniform body surface coverage.
• Keloid adjuvant radiation: 12–20 Gy in 2–4 fractions delivered within 24–48 hours of surgical excision.

Each session begins with precise patient positioning using custom immobilisation devices (shells, moulds, or vacuum bags) to ensure reproducible setup. The radiation therapist measures field size, confirms electron energy settings, positions any required bolus or shielding, and delivers the prescribed dose. Machine interlocks and independent monitor unit verification systems provide multiple layers of patient safety. Patients feel no sensation during beam delivery and are monitored by closed-circuit camera throughout.

Electron therapy offers a combination of therapeutic efficacy and normal tissue protection that is difficult to match with other radiation modalities for superficial targets.

• Sharp Dose Fall-Off: The most clinically significant advantage of electrons is their finite range. Unlike photon beams that deliver dose exponentially throughout the patient, electrons stop at a predictable depth, delivering minimal dose beyond the tumour. This sharply limits radiation to the lung (during chest wall/breast treatments), the eye (during periorbital skin treatments), and the mandible (during lip treatments).
• Excellent Surface Dose: Electrons maintain near-maximum dose at and close to the skin surface, making them ideal for treating surface lesions and skin cancers that photon beams — with their skin-sparing build-up effect — would underdose.
• Preservation of Cosmesis: For facial skin cancers, electron therapy achieves local control rates equivalent to surgery with superior cosmetic outcomes, particularly at anatomically sensitive sites such as the nasal tip, eyelid, and pinna where surgery creates significant functional and aesthetic deficits.
• Established Efficacy for Breast Boost: The EORTC 22881/10882 randomised trial demonstrated that a tumour bed boost after whole-breast irradiation reduces 10-year local recurrence rates from 10.2% to 6.2% — a clinically meaningful reduction in women under 50 with close or positive margins.
• Outpatient Treatment: All electron therapy is administered on an outpatient basis with sessions lasting 10–20 minutes, allowing patients to maintain near-normal activity throughout their treatment course.
• Cost-Effective Compared to Proton Therapy: For indications where electrons are clinically equivalent to proton beam therapy, electrons are 5–10 times less expensive, making them the preferred choice from a healthcare resource perspective.

Electron therapy is generally well tolerated but causes predictable acute skin reactions and, less commonly, late tissue changes in the treated area. The severity of side effects depends on the total dose, fraction size, treatment area, and individual patient sensitivity.

Acute side effects (occurring during or within weeks of treatment):

• Radiation Dermatitis: The most common side effect, progressing through stages of erythema (redness), dry desquamation (peeling), and in higher-dose regions, moist desquamation (weeping). Affects virtually all patients receiving skin doses above 40 Gy. Managed with moisturisers, hydrogel dressings, and wound care protocols.
• Fatigue: Generalised tiredness, particularly during extended courses. Proportional to the volume of tissue irradiated and cumulative dose.
• Hair Loss: Temporary alopecia within the treatment field. Hair typically regrows 3–6 months after treatment completion unless very high doses (above 45 Gy) cause permanent follicle damage.
• Oedema: Swelling in the treatment field, most prominent in skin and subcutaneous tissues. Usually resolves within 4–8 weeks after treatment.

Late side effects (months to years after treatment):

• Skin Fibrosis and Telangiectasia: Permanent skin thickening and fine visible blood vessels (spider veins) in the treatment field. More prominent with higher doses and larger fields.
• Hyperpigmentation or Hypopigmentation: Altered skin colouration in the irradiated area that may be permanent.
• Lymphoedema: When lymph node regions are included in the treatment field, chronic lymphoedema of the adjacent limb may develop.
• Secondary Malignancy: A very rare but recognised long-term risk of any radiation therapy. The risk is proportional to the volume of normal tissue irradiated and is outweighed by the benefit of treating the primary cancer.

Post-treatment follow-up is structured to monitor tumour response, manage side effects, and detect recurrence at the earliest treatable stage.

Immediate post-treatment care (first 4 weeks): Acute skin reactions peak 1–2 weeks after completing radiation and typically heal within 4–6 weeks. Patients receive detailed skin care instructions including gentle cleansing, non-perfumed moisturisers (aloe vera gel, aqueous cream), avoidance of sun exposure to the treated field, and prompt reporting of any wound opening, infection signs (increasing pain, warmth, purulent discharge), or unusual swelling.

Oncology clinic review schedule:

• First review: 4–6 weeks after treatment completion to assess acute toxicity resolution and initial tumour response
• Three-monthly visits for the first two years — the period of highest recurrence risk
• Six-monthly visits in years three to five
• Annual review from year five onwards, or discharge to primary care if complete remission is maintained

Imaging and assessment: Clinical examination of the treated field at each visit. Dermoscopy for skin cancer follow-up. CT chest or breast MRI for post-mastectomy and breast boost patients at 12–24 monthly intervals or as clinically indicated. PET-CT is reserved for suspected nodal or distant recurrence.

Long-term skin care: Patients are advised to apply high-SPF sunscreen (SPF 50+) to the treated field indefinitely, as irradiated skin has reduced capacity to repair UV-induced DNA damage. Any new skin lesion within or adjacent to the treated field should prompt urgent dermatology review.

The cost of electron beam therapy varies considerably depending on the country, institution, treatment indication, number of fractions, and whether it is delivered as a standalone course or as a component of a larger radiation treatment plan.

• United States: A full course of electron therapy for skin cancer (15–20 fractions) costs $15,000–$30,000 including simulation, physics planning, and daily treatment delivery. A breast tumour bed boost adds $5,000–$10,000 to the overall breast irradiation cost. Insured patients pay their deductible plus co-insurance; uninsured costs are substantially higher.
• United Kingdom (NHS): Electron therapy for cancer is fully funded through the NHS with no direct patient cost for eligible residents. Private oncology centres charge £4,000–£12,000 per course.
• India: A full electron therapy course at a JCI or NABH accredited cancer centre costs ₹80,000–₹3,00,000 ($1,000–$3,600), representing savings of 80–90% compared to the US. Leading oncology hospitals in Mumbai, Delhi, Chennai, and Bangalore are equipped with Varian and Elekta linear accelerators offering equivalent technology at a fraction of the cost.
• Thailand: $3,000–$8,000 for a standard electron therapy course at JCI-accredited cancer centres in Bangkok including all planning, physics, and treatment delivery fees.
• Turkey: €2,000–€6,000 per treatment course at accredited oncology hospitals, with very short waiting times compared to European public systems.

Factors that increase cost: custom electron field shaping (cerrobend blocks), bolus fabrication, complex planning with CT simulation, concurrent chemotherapy, hospital admission for TSET, and daily physician review charges.

For superficial cancers and skin conditions, several alternative treatment modalities exist. The optimal choice depends on lesion size, location, histology, patient preference, and available resources.

• Surgical Excision: The gold-standard for most skin cancers and the comparator against which electron therapy is benchmarked. Offers immediate histological confirmation of clear margins. Preferred when tumour size and location allow excision with acceptable functional and cosmetic outcome. Electron therapy is used when surgery would cause unacceptable morbidity or cosmetic deformity.
• Mohs Micrographic Surgery: A specialised surgical technique achieving the highest cure rates for BCC/SCC (99% for primary BCC) through complete margin assessment. Not available at all institutions; reserved for high-risk, recurrent, or anatomically critical tumours.
• Photon-Based IMRT / VMAT: Intensity-modulated radiation therapy using X-ray beams can treat superficial targets when electrons are unavailable, but delivers higher integral dose to surrounding normal tissues due to the absence of the finite range advantage. Used for deeper lesions requiring radiation where electrons cannot reach.
• Proton Beam Therapy: Like electrons, protons have a Bragg peak dose distribution with finite range. For deeply seated tumours near critical organs, protons are superior to electrons; for superficial lesions, electrons and protons are clinically equivalent but electrons are far less expensive.
• Topical and Non-Surgical Therapies: For very early, low-risk skin cancers: photodynamic therapy (PDT), imiquimod cream, 5-fluorouracil cream, and cryotherapy are alternatives. These are appropriate only for superficial BCC or actinic keratoses and are not equivalent to radiation for invasive or higher-risk lesions.
• Brachytherapy: Radioactive sources (iridium-192 or ytterbium-169) placed directly on or within the skin lesion can achieve excellent local control for selected skin cancers, offering very conformal dose delivery with minimal setup time but requiring specialist brachytherapy expertise.